|
| Agent (mechanism) | Trial description | Identifier number (status) |
|
| Necitumumab (fully human IgG1 MoAb) | Phase I trial of IMC-11F8 in patients with advanced solid tumors | NCT01088464 |
|
Phase I trial of IMC-11F8 in patients with tumors who have not responded to standard therapy |
NCT00801177 |
|
| Zalutumumab (fully human IgG1k MoAb) | Phase I/II: Zalutumumab pharmacokinetics (PK) in squamous cell carcinoma of the head and neck (SCCHN) | NCT01054625 |
|
Phase 3: DAHANCA 19: The importance of the EGFr-inhibitor zalutumumab for the outcome after curative radiotherapy for HNSCC |
NCT00496652 |
|
Phase I/II: An open, single-dose escalation study followed by a multiple dose extension of Anti-EGF receptor human MoAb (zalutumumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
NCT00093041 |
|
| Panitumumab (fully human IgG2 MoAb) | Phase II: PRISM (panitumumab regimen in second-line monotherapy of head and neck cancer) | |
|
Phase II: Radiotherapy plus panitumumab compared to chemoradiotherapy with unresected, locally advanced SCCHN |
NCT00547157 |
|
Phase II: Study of addition of panitumumab to chemoradiation therapy in subjects with locally advanced head and neck cancer |
NCT00500760 |
|
Phase I: Study panitumumab plus chemotherapy and induction chemotherapy in patients with locally advanced squamous cell cancer of the head and neck |
NCT00513383 |
|
Phase II: Trial of postoperative radiation, cisplatin, and panitumumab in locally advanced head and neck cancer |
NCT00798655 |
|
Phase II: PARTNER: panitumumab added to regimen for treatment of head and neck cancer evaluation of response |
NCT00454779 |
|
| | Phase III: Radiation therapy and cisplatin or Panitumumab in treating patients with locally advanced stage III or IV head and neck cancer | NCT00820248
|
|
Phase II: Randomized pharmacokinetic trial of chemotherapy with or without panitumumab in patients with R/M SCCHN |
NCT00756444 (Active, not recruiting) |
|
Phase II: Identification of gene expression signature for panitumumab sensitivity in untreated locally advanced SCCHN (TOP 0901) |
NCT01305772 (Recruiting) |
| Nimotuzumab (humanized IgG1 MoAb) | Phase II: Nimotuzumab in combination with TPF (cisplatin, fluorouracil, docetaxel) for head and neck squamous cell carcinoma | NCT01425736 (Recruiting) |
|
Phase III: nimotuzumab in combination with chemoradiation for nasopharyngeal cancer |
NCT01074021 (Recruiting) |
|
Phase II: Induction chemotherapy with nimotuzumab in locally advanced head and neck squamous cell carcinoma (HNSCC) |
NCT00910117 (Completed) |
|
Phase II: Safety and efficacy of target therapy combined with radiotherapy to treat senile locally advanced SCCHN |
NCT01393184 (Recruiting) |
|
Phase II: Safety and efficacy of nimotuzumab plus neoadjuvant and concurrent chemoradiotherapy to treat oropharynx and hypopharynx cancer |
NCT01516996 (Recruiting) |
|
Phase III: Study of Post-Op adjuvant concurrent Chemo-RT with or without nimotuzumab for head and neck cancer |
NCT00957086 (Recruiting) |
|
Phase II: Study comparing radiation therapy alone and radiation therapy and nimotuzumab for treatment of head and neck cancer |
NCT01345084 (Not yet open for recruitment) |
|
